SHP465 isan investigational oral stimulant medication intended to treat adults with ADHD.Two different doses of the drug treated 275 patients with ADHD more effectively than a placebo, according to a recent study led by Matthew Brams, MD, Clinical Assistant Professor at Baylor College of Medicine in Houston
Dublin-based Shire already sells Vynase and Intunic for treatment of the condition, with its ADHD drug franchise patent-protected until 2029.
“ADHD affects adults in multiple ways and, therefore, physicians need additional treatment options. Based upon this study’s findings, and pending the U.S. FDA’s review, SHP465 may provide a promising treatment option for physicians and patients alike,” said Matthew Brams, MD, lead investigator of the study.
Shire plans to submit a New Drug Application to the FDA by the end of the year and hopes to gain approval for SHP465 in late 2017.
More articles on the drug market:
FDA approves drug for treatment of 6 types of hepatitis C
Pfizer to build $350M biotech center in China
Roche’s new MS drug to hit market sooner than expected
